Regulatory & PolicyThe introduction of betting markets on drug trial results—reminiscent of sports betting—opens sweeping ethical, regulatory, and scientific questions. While claimants suggest that such markets could yield insights about the future of medicine, healthcare leaders are voicing grave concerns about transparency, data integrity, and insider trading risks. This article offers a comprehensive, analytical look at what's at stake.
Jonathan Blake·Jul 22, 2026
Regulatory & PolicyAs Trump administration policies targeting drug pricing roll out, rare disease drug manufacturers are pushing back against federal price cut initiatives. The lobbying efforts reflect broader tensions between price regulation, pharmaceutical innovation, and treatment access for vulnerable populations.
Jonathan Blake·Jul 21, 2026 
Regulatory & PolicyTestosterone therapy remains a complex subject in U.S. healthcare, with access determined by a web of guidelines, eligibility criteria, and divergent provider and policy approaches. The issue is under active discussion amid broader debates about hormone medication as well as associated public health risks, including environmental stressors such as wildfire smoke and evolving approaches for rare disease treatment.
Jonathan Blake·Jul 17, 2026 
Biopharmaceutical IndustryFollowing a recent Phase 3 failure, Pfizer has quietly discontinued a Seagen-developed antibody-drug conjugate (ADC) for solid tumors. This decision marks a significant moment for both Pfizer’s oncology ambitions and the broader ADC sector, known for high hopes and recurring setbacks.
Jonathan Blake·Jul 16, 2026 
Healthcare InvestmentThe first half of 2026 marks a pivotal change in digital health investment trends, where the dominance of AI as a differentiator is giving way to a new era defined by deep healthcare knowledge and sector expertise. Investors and founders alike are rethinking what constitutes a sustainable competitive moat in a crowded digital health marketplace.
Jonathan Blake·Jul 16, 2026 
Regulatory & PolicyThe FTC's decision to settle its high-profile lawsuit against CVS Caremark brings renewed attention to insulin pricing and the role of pharmacy benefit managers in the U.S. healthcare system. This article examines the alleged practices, settlement implications, and the broader policy debate over drug access and affordability.
Jonathan Blake·Jul 15, 2026 
Biotech InnovationSpero Therapeutics has committed over $1 billion to secure development rights for Innovent’s SP001, an investigational anti-CD40L antibody aimed at IgG4-related disease. With a Phase 2 study on the horizon for 2027, this deal highlights both the enduring value of innovative autoimmune therapies and the ongoing appetite for high-stakes biotech partnerships.
Jonathan Blake·Jul 14, 2026 
Biotech InnovationGSK’s antibody drug Jemperli showed success in a decisive Phase 2 study for patients with a rare rectal cancer subtype. This positive outcome paves the way for the company’s anticipated FDA submission and may influence future strategies for accelerated oncology drug review in the U.S.
Jonathan Blake·Jul 14, 2026 
Biotech InnovationWhile mainstream discussion centers on only two obesity-associated gene variants, hundreds of genetic factors shape individual risk. This post delves into why oversimplifying genetic causality in obesity distorts scientific understanding, clinical approaches, and public policy—and why a more nuanced view is vital for innovation.
Jonathan Blake·Jul 13, 2026 
Biopharmaceutical IndustryA new milestone in oncology drug development has been reached by GSK and Hansoh Pharmaceutical, as their antibody-drug conjugate (ADC) secures a pivotal clinical trial victory. This progress supports their cross-border collaboration and positions the partnership for near-term regulatory success in China, underscoring shifting dynamics in the global cancer therapeutics landscape.
Jonathan Blake·Jul 10, 2026 
Biotech InnovationDespite economic uncertainties, the biotech industry’s stock rally continues to outperform expectations as we move through 2026. The uptrend is reshaping investor optimism, R&D priorities, and the landscape for emerging and established biotech companies.
Jonathan Blake·Jul 5, 2026 
Biopharmaceutical IndustryThis new agreement follows recent collaborations between AstraZeneca and CSPC in obesity and chronic disease, underscoring a strategic effort to address global kidney disease challenges through innovative drug development and commercialization in both the China and global markets.
Jonathan Blake·Jul 2, 2026 